AV-104 is under clinical development by Avior Bio and currently in Phase I for Cholestasis. According to GlobalData, Phase I drugs for Cholestasis have an 83% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how AV-104’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

AV-104 overview

AV-104 is under development for the treatment of pruritus associated with chronic liver disease, cholestatic liver disease and atopic dermatitis (eczema). It is administered through the buccal route in the form of film. It is being developed based on speedit transmucosal film technology. It acts by targeting kappa Type opioid receptor and Mu-type opioid receptor.

Avior Bio overview

Avior Bio is a clinical-stage pharmaceutical company advancing therapies in pruritus (itch) in chronic liver disease (CLD) and atopic dermatitis (eczema). The company is headquartered in Holly Springs, North Carolina, the US.

For a complete picture of AV-104’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.